$SLRN
ACELYRIN, Inc. Stock $slrn

$slrn Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000196291823000007 Filed on June 15, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.91M
YoY Change
% of Gross Profit
Research & Development	$167.9M	$13.00M
YoY Change	1191.39%
% of Gross Profit
Depreciation & Amortization	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$179.8M	$16.09M
YoY Change	1018.02%
Operating Profit	-$179.8M	-$16.09M
YoY Change	1018.02%
Interest Expense	$3.446M
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$63.00K	$0.00
YoY Change
Pretax Income	-$176.5M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$176.5M	-$16.09M
YoY Change	996.98%
Net Earnings / Revenue
Basic Earnings Per Share	-$8.61	-$17.89
Diluted Earnings Per Share	-$8.61	-$17.89
COMMON SHARES
Basic Shares Outstanding	20.49M shares	899.3K shares
Diluted Shares Outstanding	20.49M shares	899.3K shares

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$289.2M
YoY Change
Cash & Equivalents	$289.2M	$212.6M
Short-Term Investments	$0.00
Other Short-Term Assets	$2.412M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$291.9M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$238.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.093M
YoY Change
Total Long-Term Assets	$6.663M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$291.9M
Total Long-Term Assets	$6.663M
Total Assets	$298.5M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.77M
YoY Change
Accrued Expenses	$19.61M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$33.66M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$0.00
YoY Change
Other Long-Term Liabilities	$11.61M
YoY Change
Total Long-Term Liabilities	$11.61M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$33.66M
Total Long-Term Liabilities	$11.61M
Total Liabilities	$45.28M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$283.5M
YoY Change
Common Stock	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$143.4M	-$56.53M
YoY Change
Total Liabilities & Shareholders Equity	$298.5M
YoY Change

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$176.5M	-$16.09M
YoY Change	996.98%
Depreciation, Depletion And Amortization	$0.00
YoY Change
Cash From Operating Activities	-$25.30M	-$14.60M
YoY Change	73.29%
INVESTING ACTIVITIES
Capital Expenditures	$238.0K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$150.4M
YoY Change
Cash From Investing Activities	$47.54M	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$129.0K	$125.0M
YoY Change	-100.1%
NET CHANGE
Cash From Operating Activities	-$25.30M	-$14.60M
Cash From Investing Activities	$47.54M	$0.00
Cash From Financing Activities	-$129.0K	$125.0M
Net Change In Cash	$22.08M	$110.4M
YoY Change	-80.0%
FREE CASH FLOW
Cash From Operating Activities	-$25.30M	-$14.60M
Capital Expenditures	$238.0K	$0.00
Free Cash Flow	-$25.54M	-$14.60M
YoY Change	74.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001962918
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-41696
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ACELYRIN, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2406735
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4149 Liberty Canyon Road
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Agoura Hills
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91301
CY2023Q1	dei	City Area Code CityAreaCode	805
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	730-0360
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock ($0.00001 par value)
CY2023Q1	dei	Trading Symbol TradingSymbol	SLRN
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	97199849	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	289194000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	267110000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	47510000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2662000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1444000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	291856000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	316064000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	5093000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	3859000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1332000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	238000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2023Q1	us-gaap	Assets Assets	298519000	usd
CY2022Q4	us-gaap	Assets Assets	319923000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10770000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5947000	usd
CY2023Q1	slrn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	14087000	usd
CY2022Q4	slrn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	5717000	usd
CY2023Q1	slrn	Accrued Compensation And Other Current Liabilities AccruedCompensationAndOtherCurrentLiabilities	5527000	usd
CY2022Q4	slrn	Accrued Compensation And Other Current Liabilities AccruedCompensationAndOtherCurrentLiabilities	4237000	usd
CY2023Q1	slrn	Severance Liability Current SeveranceLiabilityCurrent	3280000	usd
CY2022Q4	slrn	Severance Liability Current SeveranceLiabilityCurrent	0	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	33664000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15901000	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	10144000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	10291000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1315000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q1	slrn	Severance Liability Noncurrent SeveranceLiabilityNoncurrent	155000	usd
CY2022Q4	slrn	Severance Liability Noncurrent SeveranceLiabilityNoncurrent	0	usd
CY2023Q1	us-gaap	Liabilities Liabilities	45278000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	26192000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	104461636	shares
CY2023Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	104461636	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	40743522	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	40743522	shares
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	40743522	shares
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	40743522	shares
CY2023Q1	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	408000000	usd
CY2022Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	408000000	usd
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	396593000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	396593000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	269171609	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	229461636	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21653090	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21653090	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2767359	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2767359	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	140176000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4302000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-86000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-283528000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-107078000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-143352000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-102862000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	298519000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	319923000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	167920000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13003000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11913000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3082000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	179833000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	16085000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-179833000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16085000	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	147000	usd
CY2022Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3299000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-63000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-176450000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16085000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	86000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	86000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-176364000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16085000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.61
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.61
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-17.89
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-17.89
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20492101	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20492101	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	899319	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	899319	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	40743522	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	396593000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-102862000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	128735000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7139000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-176450000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	86000	usd
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	40743522	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	396593000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-143352000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	16285718	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	132620000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-42056000	usd
CY2022Q1	slrn	Temporary Equity Issuance Costs TemporaryEquityIssuanceCosts	26000	usd
CY2022Q1	slrn	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	12228923	shares
CY2022Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	124974000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1610000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16085000	usd
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	28514641	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	257594000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-56531000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-176450000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16085000	usd
CY2023Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	133057000	usd
CY2022Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7139000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1610000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	177000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	147000	usd
CY2022Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	16000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	usd
CY2023Q1	slrn	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	-825000	usd
CY2022Q1	slrn	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	923000	usd
CY2023Q1	slrn	Increase Decrease In Prepaid Expenses And Other Assets Noncurrent IncreaseDecreaseInPrepaidExpensesAndOtherAssetsNoncurrent	-2196000	usd
CY2022Q1	slrn	Increase Decrease In Prepaid Expenses And Other Assets Noncurrent IncreaseDecreaseInPrepaidExpensesAndOtherAssetsNoncurrent	148000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2990000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-54000	usd
CY2023Q1	slrn	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	3565000	usd
CY2022Q1	slrn	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	1305000	usd
CY2023Q1	slrn	Increase Decrease In Accrued Compensation And Other Current Liabilities IncreaseDecreaseInAccruedCompensationAndOtherCurrentLiabilities	-1778000	usd
CY2022Q1	slrn	Increase Decrease In Accrued Compensation And Other Current Liabilities IncreaseDecreaseInAccruedCompensationAndOtherCurrentLiabilities	-277000	usd
CY2023Q1	slrn	Increase Decrease In Severance Liability IncreaseDecreaseInSeveranceLiability	3435000	usd
CY2022Q1	slrn	Increase Decrease In Severance Liability IncreaseDecreaseInSeveranceLiability	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25329000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14572000	usd
CY2023Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	10007000	usd
CY2022Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10000000	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	47773000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	238000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	47542000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	124974000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	-129000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-129000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	124974000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22084000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	110402000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	267110000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102242000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	289194000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	212644000	usd
CY2023Q1	slrn	Offering Costs Incurred During Noncash Or Partial Noncash Transaction OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction	2180000	usd
CY2022Q1	slrn	Offering Costs Incurred During Noncash Or Partial Noncash Transaction OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1348000	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	128735000	usd
CY2022Q1	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2023Q1	slrn	Temporary Equity Convertible Conversion Ratio TemporaryEquityConvertibleConversionRatio	1
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-176500000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16100000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-176500000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-283500000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25300000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14600000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	289200000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;padding-left:27pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of its derivative tranche liability, the fair value of its common stock, stock-based compensation expense, accruals for research and development expenses, valuation of deferred tax assets, and uncertain income tax positions. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span></div>
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;padding-left:27pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, and short-term marketable securities are financial instruments that potentially subject the Company to concentrations of credit risk. As of March 31, 2023 and December 31, 2022, cash consists of cash deposited with two and one financial institution, respectively, and account balances may at times exceed federally insured limits. Subsequent to March 31, 2023, the Company deposited its cash balance in three financial institutions due to the instability in the banking sector following multiple bank failures.</span></div>The Company also has investments in money market funds, U.S. Treasury obligations, corporate debt obligations, and federal agency obligations, which can be subject to certain credit risks. The Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its financial instruments.
CY2023Q1	slrn	Concentration Risk Credit Risk Number Of Financial Institutions With Cash Deposits ConcentrationRiskCreditRiskNumberOfFinancialInstitutionsWithCashDeposits	2	institution
CY2022Q4	slrn	Concentration Risk Credit Risk Number Of Financial Institutions With Cash Deposits ConcentrationRiskCreditRiskNumberOfFinancialInstitutionsWithCashDeposits	1	institution
CY2023Q1	us-gaap	Deferred Costs DeferredCosts	3100000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	800000	usd
CY2023Q1	slrn	Asset Acquisition Separately Recognized Transactions Severance Payable Current AssetAcquisitionSeparatelyRecognizedTransactionsSeverancePayableCurrent	3300000	usd
CY2023Q1	slrn	Asset Acquisition Separately Recognized Transactions Severance Payable Noncurrent AssetAcquisitionSeparatelyRecognizedTransactionsSeverancePayableNoncurrent	200000	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	258227000	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	10144000	usd
CY2023Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	10144000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	285733000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	10291000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	10291000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	10291000	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	147000	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	10144000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	258227000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	258227000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	285819000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	86000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	285733000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	100000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2023Q1	slrn	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	1258000	usd
CY2022Q4	slrn	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	682000	usd
CY2023Q1	slrn	Prepaid Other Services Current PrepaidOtherServicesCurrent	689000	usd
CY2022Q4	slrn	Prepaid Other Services Current PrepaidOtherServicesCurrent	288000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	465000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	86000	usd
CY2023Q1	slrn	Research And Development Credit Receivable Current ResearchAndDevelopmentCreditReceivableCurrent	250000	usd
CY2022Q4	slrn	Research And Development Credit Receivable Current ResearchAndDevelopmentCreditReceivableCurrent	250000	usd
CY2023Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	0	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	138000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2662000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1444000	usd
CY2023Q1	us-gaap	Deferred Costs DeferredCosts	3082000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	774000	usd
CY2023Q1	slrn	Prepaid Research And Development Expense Noncurrent PrepaidResearchAndDevelopmentExpenseNoncurrent	1977000	usd
CY2022Q4	slrn	Prepaid Research And Development Expense Noncurrent PrepaidResearchAndDevelopmentExpenseNoncurrent	1964000	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	34000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	0	usd
CY2023Q1	slrn	Asset Acquisition Transaction Costs Current AssetAcquisitionTransactionCostsCurrent	0	usd
CY2022Q4	slrn	Asset Acquisition Transaction Costs Current AssetAcquisitionTransactionCostsCurrent	1121000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	5093000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	3859000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2023Q1	slrn	Lessee Operating Lease Monthly Payments LesseeOperatingLeaseMonthlyPayments	30500	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4440000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	808000	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	930000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3068000	usd
CY2023Q1	slrn	Accrued Liabilities And Current Liabilities Other AccruedLiabilitiesAndCurrentLiabilitiesOther	157000	usd
CY2022Q4	slrn	Accrued Liabilities And Current Liabilities Other AccruedLiabilitiesAndCurrentLiabilitiesOther	361000	usd
CY2023Q1	slrn	Accrued Compensation And Other Current Liabilities AccruedCompensationAndOtherCurrentLiabilities	5527000	usd
CY2022Q4	slrn	Accrued Compensation And Other Current Liabilities AccruedCompensationAndOtherCurrentLiabilities	4237000	usd
CY2023Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2200000	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	200000	usd
CY2023Q1	slrn	Lessee Operating Lease Square Feet Leased LesseeOperatingLeaseSquareFeetLeased	10012	sqft
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P65M
CY2023Q1	slrn	Lessee Operating Lease Annual Rent Increase Percent LesseeOperatingLeaseAnnualRentIncreasePercent	0.030
CY2023Q1	slrn	Lessee Operating Lease Rent Abatement Term LesseeOperatingLeaseRentAbatementTerm	P6M
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	34000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1300000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1300000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	100000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	26000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	375000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	386000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	397000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	409000	usd
CY2023Q1	slrn	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	280000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1873000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	558000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1315000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1315000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P65M
CY2023Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2023Q1	us-gaap	Variable Lease Payment VariableLeasePayment	100000	usd
CY2023Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	104461636	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	104461636	shares
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	40743522	shares
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	40743522	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	40743522	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	40743522	shares
CY2023Q1	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	408000000	usd
CY2022Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	408000000	usd
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	396593000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	396593000	usd
CY2022Q4	slrn	Temporary Equity Convertible Conversion Ratio TemporaryEquityConvertibleConversionRatio	0.01
CY2023Q1	slrn	Temporary Equity Voting Rights Number Of Directors TemporaryEquityVotingRightsNumberOfDirectors	3	director
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	10100000	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	100000	usd
CY2023Q1	slrn	Common Stock Outstanding Share Ownership Threshold Percentage CommonStockOutstandingShareOwnershipThresholdPercentage	0.099
CY2023Q1	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	0	usd
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	50316364	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	48458034	shares
CY2020Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	2839749	shares
CY2020Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.00002
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.9136
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9220
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.0211
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.0281
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0339
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0412
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0169
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0183
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7139000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1610000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7139000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1610000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-176450000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16085000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	21023566	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	3085044	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	531465	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	2185725	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20492101	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20492101	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	899319	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	899319	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.61
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.61
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-17.89
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-17.89
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	49128447	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32529568	shares
CY2023Q1	slrn	Valuation Allowance Deferred Tax Assets Minimum Percentage ValuationAllowanceDeferredTaxAssetsMinimumPercentage	1
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0

Files In Submission

Name	View Source	Status
slrn-20230331_cal.xml	Edgar Link	unprocessable
0001962918-23-000007-index-headers.html	Edgar Link	pending
0001962918-23-000007-index.html	Edgar Link	pending
0001962918-23-000007.txt	Edgar Link	pending
0001962918-23-000007-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
slrn-20230331.htm	Edgar Link	pending
slrn-20230331.xsd	Edgar Link	pending
slrn-20230331x10qexx311.htm	Edgar Link	pending
slrn-20230331x10qexx312.htm	Edgar Link	pending
slrn-20230331x10qexx321.htm	Edgar Link	pending
slrn-20230331_lab.xml	Edgar Link	unprocessable
slrn-20230331_pre.xml	Edgar Link	unprocessable
slrn-20230331_def.xml	Edgar Link	unprocessable
slrn-20230331_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLRN
ACELYRIN, Inc. Stock $slrn

2023 Q1 Form 10-Q Financial Statement

#000196291823000007 Filed on June 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRN ACELYRIN, Inc. Stock $slrn

2023 Q1 Form 10-Q Financial Statement

#000196291823000007 Filed on June 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRN
ACELYRIN, Inc. Stock $slrn